News | May 05, 2010

C. R. Bard to Acquire SenoRx for $213 Million

May 5, 2010 - SenoRx Inc. announced it has entered into a definitive merger agreement with C. R. Bard at a price of $11 per share, or approximately $213 million in the aggregate.

The $11 in cash for each share that SenoRx stockholders will receive at the closing of the merger represents a 14 percent premium over the closing price on May 4, and a 41 percent premium over the company's average closing price during the 90 trading days ended May 4.

The acquisition is subject to certain closing conditions specified in the definitive agreement, including regulatory approvals and the approval of SenoRx's stockholders. The transaction is expected to close in the third quarter of 2010.

The SenoRx board of directors unanimously approved the agreement and will recommend that the company's shareholders approve the transaction.

"We believe the merger represents a great opportunity for the combined companies to create product leadership by offering a broader range of high-quality breast care products to our customers," said John Buhler, SenoRx president and CEO.

Both companies offer products for the breast and oncology market.

For more information: www.senorx.com and www.crbard.com

Related Content

Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Australia's Monash Cancer Centre Treats First Early-Stage Breast Cancer Patient With Xoft System
News | Brachytherapy Systems, Women's Healthcare | May 01, 2017
iCAD Inc. announced the first early-stage breast cancer patient was treated in Australia with intraoperative radiation...
New Clinical Data on Xoft System Presented at American Brachytherapy Society Annual Meeting
News | Brachytherapy Systems, Women's Healthcare | April 20, 2017
iCAD Inc. announced that updated clinical data on the use of intraoperative radiation therapy (IORT) using the Xoft...
Concure Oncology, Breast Microseed Treatment, one day, low-dose rate brachytherapy, LDR
Technology | Brachytherapy Systems, Women's Healthcare | May 12, 2016
Concure Oncology/Breast Microseed Inc. announced the launch of its one-time, one-hour radiation treatment option for...
News | Brachytherapy Systems, Women's Healthcare | April 20, 2016
Cianna Medical Inc. announced new clinical data evaluating the Savi Scout breast localization and surgical guidance...
Gamma pro, kubtec
News | Breast Imaging | November 04, 2015
Kubtec announced the launch of the Gamma-Pro Node and Seed Location System for use in breast seed location and sentin
iCAD, Xoft Axxent, electronic brachytherapy, eBx, clinical studies, ASTRO 2015, radiation therapy

Xoft Axxent image courtesy of iCAD Inc.

News | Brachytherapy Systems | October 21, 2015
iCAD Inc. presented updated clinical data, hosted in-booth clinician presentations and showcased the latest in...
APBI, accelerated partial breast irradiation, multicatheter brachytherapy, breast conserving surgery, whole breast irradiation, WBI, ASTRO 2015
News | Brachytherapy Systems, Women's Healthcare | October 19, 2015
For some early-stage breast cancer patients, accelerated partial breast irradiation (APBI) using multicatheter...
Theragenics, Advanced Radiation Therapy LLC, AccuBoost, early stage breast cancer, brachytherapy
News | Brachytherapy Systems, Women's Healthcare | August 07, 2015
Theragenics Corp. has reached an agreement with Advanced Radiation Therapy LLC to distribute the AccuBoost technology...
Cianna Medical, SAVI Scout, breast surgical guidance system

Photo courtesy of Cianna Medical

Technology | December 16, 2014
Cianna Medical Inc. received U.S. Food and Drug Administration (FDA) clearance for the SAVI Scout surgical guidance...
Overlay Init